The group demonstrated the ability of a genetic algorithm to gauge whether cognitively normal people are at risk of near-term mental decline.
Rodent Study Suggests Low-Dose Pioglitazone May Improve Cognitive Function in Alzheimer's Patients
Originally published July 20.
The "opt-in" model ensures that customers are aware of the risks and limitations of this potentially sensitive data, but some are questioning whether the direct-to-consumer model is the appropriate mechanism for delivering information on APOE status, even with additional precautions.
Takeda will study the type 2 diabetes drug Actos as an Alzheimer's prevention treatment with the help of Zinfandel Pharmaceuticals' TOMM40 test to gauge which older adults at high risk of disease onset should be enrolled in clinical trials.
Takeda to Use Zinfandel TOMM40 Biomarker Assay for Alzheimer's Drug Study
Takeda has taken an exclusive, worldwide license for the use of Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition.